Doxorubicin-conjugated siRNA lipid nanoparticles for combination cancer therapy
Kamila Butowska1,2, Xuexiang Han1, Ningqiang Gong1
1Department of Bioengineering, University of Pennsylvania, Philadelphia, PA 19104, USA.
Abstract:
Evasion of apoptosis is a hallmark of cancer, attributed in part to overexpression of the anti-apoptotic protein B-cell lymphoma 2 (Bcl-2). In a variety of cancer types, including lymphoma, Bcl-2 is overexpressed. Therapeutic targeting of Bcl-2 has demonstrated efficacy in the clinic and is the subject of extensive clinical testing in combination with chemotherapy. Therefore, the development of co-delivery systems for Bcl-2 targeting agents, such as small interfering RNA (siRNA), and chemotherapeutics, such as doxorubicin (DOX), holds promise for enabling combination cancer therapies. Lipid nanoparticles (LNPs) are a clinically advanced nucleic acid delivery system with a compact structure suitable for siRNA encapsulation and delivery. Inspired by ongoing clinical trials of albumin-hitchhiking doxorubicin prodrugs, here we developed a DOX-siRNA co-delivery strategy via conjugation of doxorubicin to the surface of siRNA-loaded LNPs. Our optimized LNPs enabled potent knockdown of Bcl-2 and efficient delivery of DOX into the nucleus of Burkitts' lymphoma (Raji) cells, leading to effective inhibition of tumor growth in a mouse model of lymphoma. Based on these results, our LNPs may provide a platform for the co-delivery of various nucleic acids and DOX for the development of new combination cancer therapies.
Insights
Researchers developed novel lipid nanoparticles (LNPs) for co-delivery of doxorubicin (DOX) and small interfering RNA (siRNA) targeting B-cell lymphoma 2 (Bcl-2). This combined therapy effectively inhibited lymphoma tumor growth in mice by targeting cancer cell apoptosis.
Area of Science:
- Nanotechnology for Cancer Therapy
- Molecular Oncology
- Drug Delivery Systems
Background:
- Cancer cells evade apoptosis partly due to B-cell lymphoma 2 (Bcl-2) overexpression.
- Targeting Bcl-2 with agents like small interfering RNA (siRNA) shows therapeutic promise.
- Combination therapy with chemotherapy, such as doxorubicin (DOX), is under clinical investigation.
Purpose of the Study:
- To develop a co-delivery system for Bcl-2 targeting siRNA and doxorubicin (DOX).
- To utilize lipid nanoparticles (LNPs) for simultaneous delivery of these therapeutic agents.
- To evaluate the efficacy of this co-delivery system in a lymphoma model.
Main Methods:
- Conjugation of doxorubicin (DOX) to the surface of siRNA-loaded lipid nanoparticles (LNPs).
- Optimization of LNPs for efficient encapsulation and surface conjugation.
- In vitro evaluation of Bcl-2 knockdown and DOX delivery in Burkitt's lymphoma cells (Raji).
- In vivo assessment of tumor growth inhibition in a mouse model of lymphoma.
Main Results:
- Optimized LNPs achieved potent knockdown of the anti-apoptotic protein Bcl-2.
- Efficient delivery of doxorubicin (DOX) into the nucleus of lymphoma cells was observed.
- Significant inhibition of tumor growth was demonstrated in a preclinical mouse model.
Conclusions:
- The developed DOX-siRNA co-delivery LNPs offer a promising strategy for combination cancer therapy.
- This platform enables simultaneous delivery of nucleic acids and chemotherapeutics for enhanced efficacy.
- Further development of these LNPs could advance combination cancer treatment approaches.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...